Literature DB >> 856464

The distribution of [3H]vinblastine in tumor and host tissues of Nb rats bearting a transplantable lymphoma which is highly sensitive to the alkaloid.

R L Noble, P W Gout, L L Wijcik, H F Hebden, C T Beer.   

Abstract

A new transplantable lymphoma in Nb rats responded dramatically to treatment with vinblastine (VLB). A single i.p. injection of VLB, 0.8 mg/kg, caused even highly advanced tumors to regress until they were no longer palpable. or investigation of the hypothesis that the oncolytic response may reflect a special affinity of VLB for the tumor, lymphoma-bearing rats were given an i.p. injection of -e13H]VLB, and the levels of radioactivity and [3H]VLB in the tumor and host tissues were determined as a function of time. Radioactivity was concentrated by the lymphoma relative to the blood (mostly as unchanged [3H]VLB) at levels that showed only a modest decline over a period of at least 48 hr. During this time the [2H]VLB in both the plasma and whit blood cell fraction of the blood declined markedly and continuously to very low levels. Thymus and lymph nodes resembled the lymphoma in showing a long-term retention of radioactivity. The levels of radioactivity in the spleen, liver, and bone marrow were initially much higher than that in the tumor but decreased markedly with time. In addition very little of the radioactivity remaining in the spleen and liver at 48 hr was due to [3H]VLB, and by this time the VLB concentration in these tissues was much lower than in the tumor. It is suggested that the chemotherapeutic response of the lymphoma may be related to the continuing presence of a significant concentration of VLB in this tumor after the plasma VLB had fallen to very low (subantimitotic) levels.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.

Authors:  M P Rivera-Fillat; J Pallarés-Trujillo; C Domènech; M R Grau-Oliete
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

2.  A sensitive radioimmunoassay for vincristine and vinblastine.

Authors:  V S Sethi; S S Burton; D V Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography.

Authors:  O van Tellingen; J H Beijnen; W J Nooijen; A Bult
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

Authors:  O van Tellingen; A V Kuijpers; J H Beijnen; W J Nooijen; A Bult
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

5.  Fr-MLV infection induces erythroleukaemia instead of lymphoid leukaemia in mice given pituitary grafts.

Authors:  G Fontanini; F Basolo; C Garzelli; F Squartini; A Toniolo
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

Review 6.  Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.

Authors:  Luca Laraia; Grahame McKenzie; David R Spring; Ashok R Venkitaraman; David J Huggins
Journal:  Chem Biol       Date:  2015-06-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.